Key keywords: muscle growth drug, slimming jabs, lean tissue loss reduction, GLP-1 weight loss medications, body composition preservation, obesity treatment, sarcopenia risk mitigation, weight loss rebound prevention Glucagon-like peptide-1 (GLP-1) receptor agonist slimming jabs have revolutionized obesity treatment over the past five years, delivering average weight loss of 15-20% of total body weight for most users. However, a well-documented flaw of these popular medications has limited their long-term health benefits: an estimated 25-35% of the weight lost by users comes from lean muscle tissue, rather than unwanted fat mass. This muscle loss leads to a range of negative outcomes, including reduced metabolic rate, higher risk of fatigue and injury, elevated sarcopenia risk for older users, and significantly higher chances of weight regain once users stop taking the jabs. Newly published phase 2 clinical trial data from the Perelman School of Medicine at the University of Pennsylvania now reveals that an experimental muscle growth drug, an activin receptor inhibitor designed to stimulate muscle cell production, can cut lean tissue loss in GLP-1 users by 72% without reducing overall weight loss outcomes. The trial followed 247 adult participants with a BMI between 30 and 45 over a 24-week period, split evenly into two groups: one received standard semaglutide injections, while the other received semaglutide plus biweekly doses of the experimental muscle growth drug. By the end of the trial, both groups lost an average of 16.2kg of total body weight, but the combination group lost just 0.8kg of lean muscle mass, compared to 2.9kg in the semaglutide-only group. 89% of the weight lost by the combination group was fat mass, compared to 68% in the control group. Researchers also noted that participants in the combination group reported 37% lower levels of self-reported fatigue, and showed 21% better performance on functional strength tests such as stair climbing and weighted squats, compared to the control group. The research team noted that the combination therapy could address a major gap in current obesity care, particularly for vulnerable populations including adults over 65, who face disproportionately high risks of muscle loss and related complications when using weight loss jabs. Phase 3 trials of the combination therapy are scheduled to launch in 12 countries in late 2024, with preliminary results expected by mid-2026. If approved by regulatory bodies including the FDA and EMA, the treatment could become the first standard-of-care weight loss protocol prioritizing body composition alongside total weight loss, rather than focusing solely on the number on the scale.